BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Buitendijk M, Eszterhas SK, Howell AL. Gardiquimod: a Toll-like receptor-7 agonist that inhibits HIV type 1 infection of human macrophages and activated T cells. AIDS Res Hum Retroviruses 2013;29:907-18. [PMID: 23316755 DOI: 10.1089/aid.2012.0313] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Martínez-espinoza I, Guerrero-plata A. The Relevance of TLR8 in Viral Infections. Pathogens 2022;11:134. [DOI: 10.3390/pathogens11020134] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
2 Meng FZ, Liu JB, Wang X, Wang P, Hu WH, Hou W, Ho WZ. TLR7 Activation of Macrophages by Imiquimod Inhibits HIV Infection through Modulation of Viral Entry Cellular Factors. Biology (Basel) 2021;10:661. [PMID: 34356516 DOI: 10.3390/biology10070661] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
3 Wei M, Huang X, Bian C, Sun J, Ji H. ATF6-DGAT pathway is involved in TLR7-induced innate immune response in Ctenopharyngodon idellus kidney cells. Dev Comp Immunol 2021;124:104197. [PMID: 34228994 DOI: 10.1016/j.dci.2021.104197] [Reference Citation Analysis]
4 Yadav S, Verma V, Singh Dhanda R, Yadav M. Insights into the toll-like receptors in sexually transmitted infections. Scand J Immunol 2021;93:e12954. [PMID: 32762084 DOI: 10.1111/sji.12954] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Nguyen H, Gazy N, Venketaraman V. A Role of Intracellular Toll-Like Receptors (3, 7, and 9) in Response to Mycobacterium tuberculosis and Co-Infection with HIV. Int J Mol Sci 2020;21:E6148. [PMID: 32858917 DOI: 10.3390/ijms21176148] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
6 Patinote C, Karroum NB, Moarbess G, Cirnat N, Kassab I, Bonnet PA, Deleuze-Masquéfa C. Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes. Eur J Med Chem 2020;193:112238. [PMID: 32203790 DOI: 10.1016/j.ejmech.2020.112238] [Cited by in Crossref: 28] [Cited by in F6Publishing: 45] [Article Influence: 14.0] [Reference Citation Analysis]
7 Giacomelli A, de Rose S, Rusconi S. Clinical pharmacology in HIV cure research - what impact have we seen? Expert Rev Clin Pharmacol 2019;12:17-29. [PMID: 30570410 DOI: 10.1080/17512433.2019.1561272] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 Du K, Liu J, Broering R, Zhang X, Yang D, Dittmer U, Lu M. Recent advances in the discovery and development of TLR ligands as novel therapeutics for chronic HBV and HIV infections. Expert Opin Drug Discov 2018;13:661-70. [PMID: 29772941 DOI: 10.1080/17460441.2018.1473372] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
9 Enosi Tuipulotu D, Netzler NE, Lun JH, Mackenzie JM, White PA. TLR7 Agonists Display Potent Antiviral Effects against Norovirus Infection via Innate Stimulation. Antimicrob Agents Chemother 2018;62:e02417-17. [PMID: 29530841 DOI: 10.1128/AAC.02417-17] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
10 Tsai A, Irrinki A, Kaur J, Cihlar T, Kukolj G, Sloan DD, Murry JP. Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy. J Virol 2017;91:e02166-16. [PMID: 28179531 DOI: 10.1128/JVI.02166-16] [Cited by in Crossref: 77] [Cited by in F6Publishing: 91] [Article Influence: 15.4] [Reference Citation Analysis]
11 Bam RA, Hansen D, Irrinki A, Mulato A, Jones GS, Hesselgesser J, Frey CR, Cihlar T, Yant SR. TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells. Antimicrob Agents Chemother 2017;61:e01369-16. [PMID: 27799218 DOI: 10.1128/AAC.01369-16] [Cited by in Crossref: 26] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
12 Hofmann H, Vanwalscappel B, Bloch N, Landau NR. TLR7/8 agonist induces a post-entry SAMHD1-independent block to HIV-1 infection of monocytes. Retrovirology 2016;13:83. [PMID: 27905985 DOI: 10.1186/s12977-016-0316-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
13 Donninelli G, Gessani S, Del Cornò M. Interplay between HIV-1 and Toll-like receptors in human myeloid cells: friend or foe in HIV-1 pathogenesis? J Leukoc Biol 2016;99:97-105. [PMID: 26307548 DOI: 10.1189/jlb.4VMR0415-160R] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
14 Buitendijk M, Eszterhas SK, Howell AL. Toll-like receptor agonists are potent inhibitors of human immunodeficiency virus-type 1 replication in peripheral blood mononuclear cells. AIDS Res Hum Retroviruses 2014;30:457-67. [PMID: 24328502 DOI: 10.1089/AID.2013.0199] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
15 Victoria S, Temerozo JR, Gobbo L, Pimenta-Inada HK, Bou-Habib DC. Activation of Toll-like receptor 2 increases macrophage resistance to HIV-1 infection. Immunobiology 2013;218:1529-36. [PMID: 23891328 DOI: 10.1016/j.imbio.2013.06.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]